ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma

Oncogene

Volumn 30, Issue 49, 2011, Pages 4874-4886

  Singh, R R ^a   Kunkalla, K ^a   Qu, C ^a   Schlette, E ^a   Neelapu, S S ^a   Samaniego, F ^a   Vega, F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

ABCG2; ATP binding cassettes; diffuse large B cell lymphoma; GLI; hedgehog pathway

Indexed keywords

ANTINEOPLASTIC AGENT; BCL2 RELATED PROTEIN A1; BREAST CANCER RESISTANCE PROTEIN; CYCLOPAMINE; DOXORUBICIN; FUMITREMORGIN C; LUCIFERASE; MESSENGER RNA; METHOTREXATE; PROTEIN BCL 2; PROTEIN BCL XL; RECOMBINANT PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; UNCLASSIFIED DRUG; YC 137;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CANCER RESISTANCE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; DRUG TOLERANCE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LARGE CELL LYMPHOMA; LYMPH NODE; PARACRINE SIGNALING; PERITONEAL DISEASE; PLEURA EFFUSION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; SITE DIRECTED MUTAGENESIS; STROMA CELL; TUMOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

ATP-BINDING CASSETTE TRANSPORTERS; BINDING SITES; CELL LINE, TUMOR; CINNAMATES; COCULTURE TECHNIQUES; DRUG TOLERANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; ONCOGENE PROTEINS; PEPTIDE FRAGMENTS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; VERATRUM ALKALOIDS;

ERINACEIDAE;

EID: 82955237344     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.195     Document Type: Article

References (66)

1. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP. (2002). Low levels of ABCG2 expression in adult AML blast samples. Blood 100: 4594-4601. (Pubitemid 35429703)
2. Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS et al. (2007). The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120(Suppl 12): 1-39. (Pubitemid 46732571)
3. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337-5339. (Pubitemid 28551112)
4. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398. (Pubitemid 29222564)
5. Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ et al. (2007). Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 109: 3409-3416. (Pubitemid 46572530)
6. Armitage JO. (2007). How I treat patients with diffuse large B-cell lymphoma. Blood 110: 29-36. (Pubitemid 47026815)
7. Bailey-Dell KJ, Hassel B, Doyle LA, Ross DD. (2001). Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim Biophys Acta 1520: 234-241. (Pubitemid 32868794)
8. Barnes EA, Heidtman KJ, Donoghue DJ. (2005). Constitutive activation of the shh-ptc1 pathway by a patched1 mutation identified in BCC. Oncogene 24: 902-915. (Pubitemid 40216098)
9. Baumann P, Mandl-Weber S, Volkl A, Adam C, Bumeder I, Oduncu F et al. (2009). Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 8: 366-375.
10. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP et al. (2004). Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10: 7896-7902. (Pubitemid 39587528)
11. Bhatia N, Thiyagarajan S, Elcheva I, Saleem M, Dlugosz A, Mukhtar H et al. (2006). Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J Biol Chem 281: 19320-19326. (Pubitemid 44035437)
12. Bigelow RL, Chari NS, Unden AB, Spurgers KB, Lee S, Roop DR et al. (2004). Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J Biol Chem 279: 1197-1205. (Pubitemid 38082643)
13. Bleau AM, Huse JT, Holland EC. (2009). The ABCG2 resistance network of glioblastoma. Cell Cycle 8: 2936-2944.
14. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F et al. (2004). ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 109: 848-854. (Pubitemid 38500741)
15. Damiani D, Tiribelli M, Michelutti A, Geromin A, Cavallin M, Fabbro D et al. (2010). Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk Res 34: 942-945.
16. Dean M, Allikmets R. (2001). Complete characterization of the human ABC gene family. J Bioenerg Biomembr 33: 475-479. (Pubitemid 34052573)
17. Desch P, Asslaber D, Kern D, Schnidar H, Mangelberger D, Alinger B et al. (2010). Inhibition of GLI, but not smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene 29: 4885-4895.
18. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR et al. (2007). Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13: 944-951. (Pubitemid 47222041)
19. Diestra JE, Scheffer GL, Catala I, Maliepaard M, Schellens JH, Scheper RJ et al. (2002). Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol 198: 213-219. (Pubitemid 35243879)
20. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670. (Pubitemid 29018757)
21. Eichberger T, Sander V, Schnidar H, Regl G, Kasper M, Schmid C et al. (2006). Overlapping and distinct transcriptional regulator properties of the GLI1 and GLI2 oncogenes. Genomics 87: 616-632.
22. Fernandez M, Pino AM, Figueroa P, Rodriguez JP. (2010). The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate. J Cell Biochem 111: 130-137.
23. Fidler IJ. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458. (Pubitemid 37328849)
24. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328: 1002-1006. (Pubitemid 23095683)
25. Gottesman MM. (2002). Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627. (Pubitemid 34177898)
26. Gottesman MM, Fojo T, Bates SE. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58. (Pubitemid 37328807)
27. Grigorieva I, Thomas X, Epstein J. (1998). The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol 26: 597-603. (Pubitemid 28307527)
28. Hegde GV, Peterson KJ, Emanuel K, Mittal AK, Joshi AD, Dickinson JD et al. (2008). Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. Mol Cancer Res 6: 1928-1936.
29. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A et al. (2001). Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-over-expressing cells. Cancer Res 61: 6635-6639. (Pubitemid 32896477)
30. Hu LL, Wang XX, Chen X, Chang J, Li C, Zhang Y et al. (2007). BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. Carcinogenesis 28: 1740-1744. (Pubitemid 47289036)
31. Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E. (2004). Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Ann Hematol 83: 414-419. (Pubitemid 38877961)
32. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T et al. (2002). Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 97: 626-630. (Pubitemid 34087801)
33. Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J et al. (2003). Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 9: 3052-3057. (Pubitemid 36993267)
34. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA et al. (2009). Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma. Mod Pathol 22: 1312-1320.
35. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE et al. (2004). The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279: 24218-24225. (Pubitemid 38725283)
36. Krishnamurthy P, Schuetz JD. (2006). Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46: 381-410. (Pubitemid 43271195)
37. Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC et al. (2009). Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia 23: 170-177.
38. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S et al. (2010). Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 16: 483-489.
39. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B et al. (1999). Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8-13. (Pubitemid 29062946)
40. Mueller MM, Fusenig NE. (2004). Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4: 839-849. (Pubitemid 39472951)
41. Murone M, Rosenthal A, de Sauvage FJ. (1999). Hedgehog signal transduction: from flies to vertebrates. Exp Cell Res 253: 25-33.
42. Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T et al. (2005). Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 68: 422-431. (Pubitemid 41160973)
43. Quandt K, Frech K, Karas H, Wingender E, Werner T. (1995). MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 23: 4878-4884. (Pubitemid 3008389)
44. Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP et al. (2010). Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 29: 6314-6322.
45. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. (2000). Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60: 47-50. (Pubitemid 30058728)
46. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M et al. (2003). Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89: 1971-1978. (Pubitemid 37533279)
47. Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE et al. (2000). The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun 271: 42-46. (Pubitemid 30444853)
48. Rodriguez C, Commes T, Robert J, Rossi JF. (1993). Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma. Leuk Res 17: 149-156. (Pubitemid 23075462)
49. Sacedon R, Diez B, Nunez V, Hernandez-Lopez C, Gutierrez-Frias C, Cejalvo T et al. (2005). Sonic hedgehog is produced by follicular dendritic cells and protects germinal center B cells from apoptosis. J Immunol 174: 1456-1461.
50. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A. (2004). ABCG2-a transporter for all seasons. FEBS Lett 567: 116-120.
51. Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F. (2002). Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 118: 147-150. (Pubitemid 34779530)
52. Schmittgen TD. (2001). Real-time quantitative PCR. Methods 25: 383-385. (Pubitemid 34164010)
53. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. (2007). Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 26: 5674-5679. (Pubitemid 47267845)
54. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R et al. (2006). Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 12: 6565-6572. (Pubitemid 44799732)
55. Singh RR, Cho-Vega JH, Davuluri Y, Ma S, Kasbidi F, Milito C et al. (2009). Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res 69: 2550-2558.
56. Singh RR, Kim JE, Davuluri Y, Drakos E, Cho-Vega JH, Amin HM et al. (2010). Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia 24: 1025-1036.
57. Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD et al. (2004). Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 18: 78-83. (Pubitemid 38159442)
58. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A. (2002). BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16: 1443-1447.
59. Taipale J, Beachy PA. (2001). The Hedgehog and Wnt signalling pathways in cancer. Nature 411: 349-354. (Pubitemid 32467044)
60. To KK, Zhan Z, Bates SE. (2006). Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol 26: 8572-8585. (Pubitemid 44748589)
61. Tsunoda S, Okumura T, Ito T, Kondo K, Ortiz C, Tanaka E et al. (2006). ABCG2 expression is an independent unfavorable prog-nostic factor in esophageal squamous cell carcinoma. Oncology 71:251-258.
62. Uggla B, Stahl E, Wagsater D, Paul C, Karlsson MG, Sirsjo A et al.(2005). BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 29: 141-146. (Pubitemid 39647507)
63. Winklmayr M, Schmid C, Laner-Plamberger S, Kaser A, Aberger F, Eichberger T et al. (2010). Non-consensus GLI binding sites in Hedgehog target gene regulation. BMC Mol Biol 11: 2.
64. Yasuda S, Kobayashi M, Itagaki S, Hirano T, Iseki K. (2009).Response of the ABCG2 promoter in T47D cells and BeWo cells to sex hormone treatment. Mol Biol Rep 36: 1889-1896.
65. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K et al. (2004).Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10: 1691-1697. (Pubitemid 38435560)
66. Yuen AR, Sikic BI. (1994). Multidrug resistance in lymphomas. J Clin Oncol 12: 2453-2459. (Pubitemid 24346720)